Sun Pharmaceutical Industries Ltd (SUNPHARMA) — shareholding pattern, promoter holding, financials and share price
About Sun Pharmaceutical Industries Ltd (SUNPHARMA)
Sun Pharmaceutical Industries Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SUNPHARMA and on the BSE under scrip code 524715. Its ISIN is INE044A01036.
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. [1] It is the largest pharmaceutical company in India. [2]
Sun Pharmaceutical Industries Limited is a global specialty generic and innovative medicines company that researches, manufactures and markets branded generics, generics, complex formulations, APIs and innovative specialty products across over 100 countries, with a 40-site global manufacturing footprint and roughly 43,000 employees focused on dermatology, ophthalmology, oncology and chronic therapies.
The company reported FY25 consolidated sales of Rs 520 billion and has delivered a 19% sales CAGR since FY10, with Innovative Medicines growing to 20% of revenues; Sun Pharma combines a diversified geographic split—India 33% and international 67%—with deep backward integration into APIs and multiple dosage-form capabilities.
Listed peers in Pharmaceuticals: Divis Laboratories Ltd, Torrent Pharmaceuticals Ltd, Cipla Ltd, Zydus Lifesciences Ltd, Lupin Ltd, Mankind Pharma Ltd.
Valuation & Returns
10 Jul 2026At ₹1,935.25 a share on 10 Jul 2026, Sun Pharmaceutical Industries Ltd (SUNPHARMA) was valued at a price-to-earnings ratio of 40.15x against an industry P/E of 36.41x and a price-to-book of 5.56x on a book value of ₹348.31 per share as of Mar 2026. Solomo computes return on equity of 13.84% and return on capital employed of 17.53% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 40.15x
- Industry P/E
- 36.41x
- P/B
- 5.56x
- EPS (TTM)
- ₹48.2
- Book value / share
- ₹348.31
- ROE
- 13.84%
- ROCE
- 17.53%
- ROA
- 10.63%
- Debt / equity
- 0.06x
- Dividend yield
- 0.83%
- EBITDA margin
- 31.6%
- 52-week range
- ₹1,547.25 – ₹1,953.75
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Sun Pharmaceutical Industries Ltd (SUNPHARMA) reported revenue of ₹58,462 crore, net profit of ₹11,509 crore and earnings per share of ₹47.84. That compares with revenue of ₹52,578 crore and net profit of ₹10,965 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹14,612 crore and net profit ₹2,710 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 38,654 | 43,886 | 48,497 | 52,578 | 58,462 |
| Net profit (₹ cr) | 3,389 | 8,513 | 9,610 | 10,965 | 11,509 |
| EPS (₹) | 13.64 | 35.32 | 39.91 | 45.55 | 47.84 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 11.50% | 8.01% | -0.09% | 11.19% |
| Profit growth | - | 25.51% | 15.77% | 5.32% |
| Stock price CAGR | 10% | 23% | 22% | 15% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 54.48% of Sun Pharmaceutical Industries Ltd (SUNPHARMA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 14.53% and domestic institutional investors (DII) hold 22.18%. Promoters have pledged 1.6% of their holding. Market capitalisation was ₹4,64,331 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: Life Insurance Corporation Of India 5.53%, Icici Prudential Value Fund 3.72%, Sbi Nifty 50 Etf 2.36%, Nps Trust- A/C Hdfc Pension Fund Management Limited Scheme E - Tier I 1.88%, Nippon Life India Trustee Ltd-A/C Nippon India Large Cap Fund 1.38%, Government Pension Fund Global 1.03%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 54.48% | 1.6% | 14.53% | 22.18% | 45.52% |
| Mar 2026 | 54.48% | 1.4% | 15.93% | 21.11% | 45.52% |
| Dec 2025 | 54.48% | 1% | 16.12% | 20.82% | 45.52% |
| Sep 2025 | 54.48% | 1% | 16.55% | 20.23% | 45.52% |
| Jun 2025 | 54.48% | 0.9% | 17.26% | 19.5% | 45.52% |
| Mar 2025 | 54.48% | 0.9% | 17.96% | 18.7% | 45.52% |
| Dec 2024 | 54.48% | 0.7% | 18.05% | 18.55% | 45.52% |
| Sep 2024 | 54.48% | 0.8% | 18.02% | 18.61% | 45.52% |